A Phase II Trial of Interferon Alpha-2a and Carboplatin in Patients with Advanced Malignant Mesothelioma

We defined the antitumor activity, toxicity, and tolerability of a combined chemoim-munotherapy approach in patients with advanced malignant mesothelioma using daily low-dose integeron alpha-2a and carboplatin given every 4 weeks. This was a phase II study of 15 patients with surgically unresectable...

Full description

Saved in:
Bibliographic Details
Published in:Cancer investigation 1999, Vol.17 (3), p.195-200
Main Authors: O'Reilly, Eileen M., Ilson, David H., Saltz, Leonard B., Heelan, Robert, Martin, Lisa, Kelsen, David P.
Format: Article
Language:English
Subjects:
Aged
Antineoplastic agents
Antineoplastic Combined Chemotherapy Protocols - therapeutic use
Biological and medical sciences
Carboplatin
Carboplatin - therapeutic use
Combined treatments (chemotherapy of immunotherapy associated with an other treatment)
Disease Progression
Dose-Response Relationship, Drug
Drug Administration Schedule
Female
Humans
Interferon
Interferon-alpha - therapeutic use
Male
Medical sciences
Mesothelioma
Mesothelioma - drug therapy
Mesothelioma - mortality
Middle Aged
Pharmacology. Drug treatments
Phase II
Recombinant Proteins
Survival Rate
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:We defined the antitumor activity, toxicity, and tolerability of a combined chemoim-munotherapy approach in patients with advanced malignant mesothelioma using daily low-dose integeron alpha-2a and carboplatin given every 4 weeks. This was a phase II study of 15 patients with surgically unresectable or metastatic malignant mesothelioma. All patients had measurable or assessable disease. No prior chemotherapy or immunotherapy was allowable. Carboplatin was given at 150 mg/m2 daily on days 1-3 and integeron alpha-2a at 3 million units subcutaneously daily throughout the study. Treatment was recycled every 28 days. Therapy was continued until disease progression. Fifteen patients were assessable for toxicity and 14 for response. One partial response (7%, 95% CI, 0-20%), with a response duration of 40 weeks, was seen. Most patients had early progression of disease. Toxicity was tolerable, and grade III/ IV toxicity was uncommon. The median time to progression was 14 weeks (range, 1-52 weeks). The median survival was 25 weeks (range, 8-66 weeks). The combination of low-dose integeron alpha-2a and carboplatin did not result in greater antitumor activity than that reported for single-agent carboplatin in advanced malignant mesothelioma. Although toxicity was mild, carboplatin and low-dose interferon, given at this dose and schedule, cannot be recommended for this patient group.
ISSN:0735-7907
1532-4192
DOI:10.3109/07357909909021421